Homocysteine as a potential biochemical marker for depression in elderly stroke survivors by Pascoe, Michaela et al.
Homocysteine as a potential biochemical
marker for depression in elderly stroke
survivors
Michaela C. Pascoe1*, Sheila G. Crewther4, Leeanne M. Carey3,
Kate Noonan3,4, David P. Crewther1 and Thomas Linden2
1Brain Sciences Institute, Swinburne University, Melbourne, Australia; 2Institute of Neuroscience and Physiology,
University of Gothenburg, Gothenburg, Sweden; 3National Stroke Research Institute, Florey Neurosciences Institutes,
Melbourne, Australia; 4School of Psychological Science, La Trobe University, Melbourne, Australia
Abstract
Background: Elderly stroke survivors have been reported to be at risk of malnutrition and depression.
Vitamin B-related metabolites such as methylmalonic acid and homocysteine have been implicated in
depression.
Objective: We conducted a study exploring the relationship between homocysteine and post-stroke
depression.
Design: Three methodologies were used: Observational cohort study of elderly Swedish patients (n149)
1.5 years post-stroke, assessed using Diagnostic and Statistical Manual of Mental Disorders, Montgomery
A˚sberg Depression Rating Scale and serum blood levels of methylmalonic acid and homocysteine.
Results: Homocysteine significantly correlated with depressive symptomatology in stroke survivors
(b0.18*). Individuals with abnormal levels of methylmalonic acid and homocysteine were almost twice
more likely to show depressive symptomatology than those with normal levels (depressive symptoms 22%; no
depressive symptoms 12%). Comparison of methylmalonic acid and homocysteine levels with literature
data showed fewer stroke survivors had vitamin deficiency than did reference individuals (normal range
66%; elevated 34%).
Conclusions: Homocysteine is significantly associated with depressive symptomatology in elderly Swedish
stroke survivors.
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D
epression is particularly prevalent among stroke
survivors, affecting approximately a third of
individuals (1). Post-stroke depression is asso-
ciated with reduced functional ability and poorer out-
come (2), making the prevention and management of
post-stroke depression an important area of research.
Vitamin deficiencies are particularly common among
stroke survivors and similar to post-stroke depression
are associated with poor outcome (3).
Vitamin B12 and folate are required dietary vitamin
nutrients involved in the biosynthesis of depression-
related serotonin, dopamine and norepinephrine (4).
Folic acid and vitamin B12 are also required for the
synthesis of the methionine, by methionine synthase,
from the amino acid homocysteine (tHcy). Methionine
cannot be synthesised from tHcy without an adequate
supply of folate and vitamin B12, so vitamin deficiency
results in an elevated level of tHcy.
Methylmalonyl coenzyme A is the coenzyme A linked
form of methylmalonic acid (MMA). Vitamin B12 is
required for the biosynthesis of MMA coenzyme A, to
succinyl coenzyme A in the citric acid cycle. Therefore,
insufficient vitamin B12 levels are associated with in-
creased levels of MMA (5).
High tHcy is associated with a 70% increased risk of
clinical depression in elderly individuals (6), while folate
is decreased in blood samples of depressed individuals
(7). Low folate is associated with a worse than expected
response to selective serotonin reuptake inhibitor (SSRI)
and tricyclic antidepressants, while higher folate levels are
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associated with better response (8, 9). Supplementation
with folate has been shown to have antidepressant effects
and to be as effective as conventional antidepressants
in some cases (6, 10, 11). Higher tHcy contributes to
depression-related naturally occurring cell death or
apoptosis (7, 12).
Thus, as elderly stroke patients are at particular risk of
malnourishment (3) and depression (1) and as B vitamin-
related factors such as folate and Vitamin B12 related to
tHcy and MMA are implicated in the aetiology of clinical
depression, it is particularly important to clarify if these
biomarkers are associated with the depressive sympto-
matology seen in at least one third of elderly stroke
patients (1).
We sought to systematically review the role of MMA,
tHcy, folate and Vitamin B12 and depressive symptoma-
tology in stroke survivors. To do this, we examined the
vast amount of literature relating to the relationship
between B vitamins and clinical depression, and between
B vitamins and stroke. No studies were found to directly
address the possible role of folate, vitamin B12, tHcy or
MMA as contributing to depressive symptomatology in a
post-stroke sample.
Thus, we aimed to explore the relationship between
tHcy and depressive symptomatology among chronic
stroke survivors, by determining the percentage of
individuals diagnosed with clinical depression and vita-
min deficiency. We further aimed to determine if elevated
tHcy contributed to the observed depressive symptoma-
tology and to clarify the percentage of elderly stroke
survivors with abnormal tHcy and MMA, compared to a
matched non-stroke affected population. Thus, we com-
pared a population of elderly Swedish stroke survivors to
a matched non-stroke population of elderly Swedish
individuals (13) to assess nutrition-induced risk for
deficiency in the depression-related metabolites MMA
and tHcy, 1.5 years post-stroke.
Method
Subjects
Participant selection has been described in detail pre-
viously (14). Briefly, participants (n149) were drawn
from the ‘Gothenburg 70 Stroke Study,’ which con-
sisted of individuals admitted to Sahlgrenska University
Hospital, Gothenburg, Sweden, between 1 February 1993
and 17 May 1994, aged at least 70 years and presenting
with an acute cerebrovascular neurological deficit, as
diagnosed by routine investigations by the physician on
call and acute computer tomography (CT) scan. Exclu-
sion from the study applied if coma, cerebral tumour,
extracerebral or subarachnoid haemorrhage, previous
cerebral lesion requiring ongoing care, or a requirement
for specialised neurological care was present. Participa-
tion was limited also to individuals who received a bed in
the stroke unit, presented with symptoms for a time
period no greater than 7 days prior to admission and were
not residing in a nursing home at the time of admission.
There was no control participant data available for this
cohort study.
Study protocol
Stroke patients were contacted by mail 1 year after stroke
and subsequently by phone, to arrange a hospital-based
appointment. When unable to attend the hospital-based
appointment (n15; 10%), interviews took place in
participants’ homes. Informed consent was obtained after
having provided verbal and written information to
participants or nearest relatives when relevant. Ethics
approval was granted by The Ethics Committee for
Medical Research at the University of Gothenburg.
Biomarkers collection
MMA was analysed from venous blood drawn into gel
tubes (filled to at least three quarters full), turned over at
least 10 times and centrifuged at 2300g for 10 min. Serum
was separated and kept at room temperature before
analysis with gas chromatography/mass spectrometry.
Samples for tHcy were drawn in Li-heparin gel tubes
(filled to at least three quarters full) turned over at least
five times within 30 min and centrifuged at 2300G for
10 min, before analysis. Reference values from the
Uddevalla Hospital, Uddevalla, Sweden were B0.37
mmol/L for serum MMA,B15 mmol/L for serum
tHcy (13).
Diagnostic criteria
Depression assessments were conducted by a neurologist/
psychiatrist who was unaware of the type, size and
location of the index stroke at the time of the investiga-
tion and throughout the diagnostic procedure. Clinical
depression was diagnosed according to DSM-III-R
criteria (15) using algorithms based on psychiatric inter-
view and neuropsychiatric examination. Depressive
symptomatology was assessed using the Montgomery
A˚sberg Depression Rating Scale (MADRS). Adjusted
MADRS scores are compiled based on information
obtained from 10 related criteria, such as suicidal
thoughts and pessimistic thoughts. Individuals are given
a score for each of these measures that are complied into
an overall depressive score. Missing data, however, on
some of these criteria among cases made MADRS score
adjustment implausible in the current study; therefore,
raw score data were used as a conservative measure of
depressive symptoms. It should be noted, however, that
the raw score data used in the present study may
underestimate the degree of depressive symptomatology
among the sample.
Assessment consisted of a semi-structured diagnostic
psychiatric interview, neuropsychological tests and a
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neurological examination. Assessment instruments were
the same as those used in the Gerontological and
Geriatric Population Studies and the Prospective Popula-
tion Study on Women and included a semi-structured
psychiatric diagnostic interview with the Comprehensive
Psychopathological Rating Scale (16). This form of
clinical depression diagnosis was used to categorically
classify individuals as either depressed or not depressed,
in order to determine the percentage of these individuals
with and without elevated MMA and tHcy. For the
purpose of multiple regression analysis and descriptive
statistics, raw continuous MADRS scores only were used.
Control reference data
Control participant reference data were sourced from
PubMed and drawn from a population-based study of
elderly Swedish individuals (13). This study provided
information regarding tHcy and MMA levels in non-
stroke elderly Swedish individuals and laboratory cutoff
points for vitamin deficiency. This control data were
compared with the stroke cohort data to assess if elderly
stroke survivors were more at risk of nutritional deficien-
cies, as indicated by MMA and tHcy 1.5 years post-
stroke, than were the non-stroke elderly individuals.
Statistical methods
Statistical analysis was conducted using the SPSS version
18 package. Hierarchical Multiple Regression was used to
determine the variance explained by tHcy after account-
ing for age and gender. Outliers were screened using box
plots; linearity and homoscedasticity were checked
using scatter plots of standardized residuals. Normality
was assessed using a histogram and normal probability
plots. Pearson’s Correlation was used to determine
multi-collinearity between predictors. Independent
sample t tests were used to determine the differences in
MMA and tHcy expression between stroke survivors and
reference data from non-stroke individuals.
Results
Characteristics of the observational cohort study population
Table 1 illustrates the characteristics of stroke survivors
according to gender. The study cohort consisted of 243
patients at baseline (stroke admission). By the time of
hospital follow-up, at 1.5 years post-stroke (SD, 0.4
years), 32% (n77) had passed away and 7% (n17)
declined the invitation to participate, leaving 149 indivi-
duals. Two thirds, 65% (n97) of individuals were
female, and 35% (n52) were male. Patients mean age
at follow-up was 81 years (SD 5.3 years). The mean age of
the female survivors was approximately 2 years older
than that of the male participants. Female MADRS
scores were approximately three points higher than male
participants. tHcy was comparable between males and
females.
Rates of depression and vitamin deficiency among stroke
survivors
Of the individuals with elevated metabolites, 22% showed
depressive symptoms, while 12% showed no depressive
symptoms. Of the individuals with no elevated metabo-
lites, only 16% showed depressive symptoms, while 37%
showed no depressive symptoms. Individuals with ele-
vated tHcy or MMA were almost twice as likely to be
classified as clinically depressed, according to Diagnostic
and Statistical Manual of Mental Disorders (DSM-III)
criteria, than were individuals who did not show elevated
tHcy or MMA.
As expected, MMA and tHcy were significantly
correlated (r0.17, n115, p0.03).
Multiple regression
Table 2 shows the results of the Hierarchical Multiple
Regression used to determine the predictive roles of age,
gender and peripheral blood plasma tHcy expression on
raw MADRS scores. Age and gender were entered
together into the first block, as previous research with
this particular cohort indicated that both contributed to
depressive symptoms (1). Then, tHcy was entered into the
second block to determine if it contributed to the
MADRS scores. Age and gender together explained
3.2% of the variance in depression scores, with neither
gender nor age predicting depression scores (F(2, 115)
1.88, p0.16). The addition of tHcy to the model
increased the amount of variance explained by 3.3%,
with tHcy significantly contributing to MADRS
scores (F(1, 114)3.99, pB0.05). Table 2 displays the
Table 1. Age, Montgomery A˚sberg Depression Rating Scale
(MADRS) scores, homocysteine (tHcy) and methylmalonic acid
(MMA) in stroke survivors.
N Mean (SE) Median
Female 97
Age 82 (0.55) 83.08
MADRS 11.40 (0.90) 9
tHcy 79 12.24 (0.64) 11
MMA 78 0.27 (0.01) 0.25
Male 52
Age 79.23 (0.64) 78.99
MADRS 8.23 (0.90) 7
tHcy 39 12.05 (0.69) 11
MMA 38 0.24 (0.01) 0.23
15 mmol/Lcut off point of tHcy.0.37 mmol/Lcut off point of
serum MMA. Higher MADRS scores represent more depressive
symptomatology. Means, Medians and SE Including Age, Gender, tHcy
Expression and MADRS Scores, Presented by Gender.
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coefficients (b) the Standard Error of the coefficients
(SE B) and standardised beta (b) values of the model.
Characteristics of the study population as compared to
literature sourced control data
As no control data were available for the observation
cohort study, reference values of tHcy and MMA
expression in elderly non-stroke-affected Swedish indivi-
duals was sourced from the literature (13). One sample
t tests were used to show that stroke survivors
differed significantly in MMA t(147)3.528,
pB0.001 (Stroke0.20; Control0.16) and tHcy levels,
t(148)9.64, pB0.001 (Stroke9.64; Control14.7).
Surprisingly, 49% of non-stroke individuals showed
elevated tHcy and MMA. Among stroke survivors, 34%
of individuals had elevated tHcy or and MMA as
compared to the literature-sourced reference values (13).
Discussion
To our knowledge this is the first observational cohort
study to examine the relationship between depressive
symptoms and tHcy, a sensitive measure of folate and
vitamin B12 status (17), in an at-risk elderly post-stroke
population.
Individuals with elevated tHcy or MMA were almost
twice more likely to be classified as clinically depressed
according to DSM-III criteria than were individuals who
did not show elevated tHcy or MMA. The multiple
regression showed that peripheral plasma tHcy was
significantly associated with MADRS depression scores
after having controlled for age and gender. This suggests
that tHcy is a predictor of depressive symptomatology in
stroke survivors. These findings are consistent with
previous research suggesting that in non-stroke indivi-
duals, increased folate and vitamin B12 may decrease
depressive symptoms by influencing the production of
depression-related neurotransmitters (4).
Recently, research has begun to focus also on the role
of apoptosis in stroke-related depression (18). Apoptosis
is elevated among depressed individuals (14) and con-
sidered to be a risk factor for depressive disorder (19).
The metabolite tHcy is toxic to neurons (20). Thus, tHcy
may be contributing to depressive symptomatology, in
part, via regulation of depression-related apoptosis.
In the present study, no gender differences were found
in tHcy expression. Females did, however, have higher
MADRS scores than males. This finding is consistent
with previous analysis using data from this cohort (1) and
the general trend of higher reported levels of subjective
depression among females (21).
The present research additionally aimed to explore if
stroke survivors were more at risk of vitamin deficiency,
as indicated by MMA and tHcy levels, than was a
comparable non stroke affected population. Previous
research has indicated that age-related biological and
physiological changes make the elderly particularly
vulnerable to vitamin deficiency (22). Dysphagia and
subsequent eating difficulties in up to 80% of patients
with acute stroke has been reported to further increase
this risk of malnutrition (3). Stroke survivors have
additionally been shown to be particularly at risk of
clinical depression (1); thus, in the present study it was
important to clarify the presence of nutritional deficien-
cies among stroke survivors in depression-associated
markers. In this cohort, Swedish stroke survivors were
no more likely to show elevated MMA or tHcy, 1.5
years after a stroke, compared to elderly Swedish non-
stroke-affected individuals. In fact, among stroke survi-
vors, a smaller percentage of individuals were found to
be vitamin deficient than in the reference group.
However, caution should be exercised when interpreting
these results. In the present study, nearly one third of
stroke survivors were found to be vitamin deficient as
indicated by elevated tHcy and MMA, and thus should
still be considered an ‘at risk’ group. This is particularly
true as tHcy elevation was associated with depressive
symptomatology in the stroke surviving cohort. Elderly
individuals are in general identified as at risk of
nutritional deficiencies, due to an extensive variety of
factors spanning from psychosocial, social, financial,
medical and cognitive (22). Very high levels of nutri-
tional deficiency among the control group may have
overshadowed the observed deficiency among stroke-
surviving individuals. Indeed, almost half of the elderly
Swedes from the reference study had elevated MMA
and tHcy (21). It may also be the case that these
particular stroke survivors showed less vitamin defi-
ciency than the non-stroke-affected comparison popula-
tion due to the typically high level of medical care, likely
hospitalisation and monitoring given post-stroke in
Sweden. Finally, the stroke experience may prompt
increased self awareness regarding health and well-being,
Table 2. Coefficients, standard error of the coefficients and stan-
dardised beta values of the regression model.
B SE B b R2
Step 1 0.03
Constant 12.42 12.42
Age 0.13 0.15 0.08
Gender 3.08 1.63 0.18
Step 2 0.06
Constant 12.08 12.26
Age 0.05 0.15 0.03
Gender 3.13 1.61 0.18
tHcy 0.28 0.14 0.18*
Note: R20.03 for Step 1: DR20 .06 for Step 2 (pB0.05).
*Significant at pB0.05.
Michaela C. Pascoe et al.
4
(page number not for citation purpose)
Citation: Food & Nutrition Research 2012, 56: 14973 - DOI: 10.3402/fnr.v56i0.14973
which in conjunction with high-level medical care may
have encouraged stroke survivors to consume more
nutritionally sound foods.
Conclusions
The present observational cohort study demonstrates
that MMA and tHcy are associated with a depression
diagnosis post-stroke, and that high tHcy expression is a
significant predictor of depressive symptoms post-stroke
after accounting for age and gender. The results are
consistent with the argument that nutritional factors
post-stroke are important in understanding depressive
disorder and its prevention. This observational cohort
data additionally demonstrates that elderly Swedish
stroke survivors do not have more B vitamin deficiencies
when compared to elderly non-stroke-affected Swedish
individuals. It is important to note, however, that this
data were collected in the 1990s and possible changes in
nutritional intake since this time among stroke survivors
may influence the present day validity of these findings.
While we do not anticipate this to be the case, we do
suggest that replicating the present study to ensure the
validity of the results is recommended.
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